EA200101231A1 - Нафталинмочевины как усилители поглощения глюкозы - Google Patents
Нафталинмочевины как усилители поглощения глюкозыInfo
- Publication number
- EA200101231A1 EA200101231A1 EA200101231A EA200101231A EA200101231A1 EA 200101231 A1 EA200101231 A1 EA 200101231A1 EA 200101231 A EA200101231 A EA 200101231A EA 200101231 A EA200101231 A EA 200101231A EA 200101231 A1 EA200101231 A1 EA 200101231A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkyl
- independently
- substituted
- heteroaryl
- aryl
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- -1 NAPHTHALINUM UREAS Chemical class 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000003623 enhancer Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 206010007134 Candida infections Diseases 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 102000003746 Insulin Receptor Human genes 0.000 abstract 2
- 108010001127 Insulin Receptor Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
Раскрываются соединения формулы (I), где Rи Rявляются заместителями в кольцах А и означают независимо друг от друга -SONR, -C(O)NR, -NRSOR, -NRC(O)R, -SOOR, -C(O)OR, -OSORили -OC(O)R, Rи Rозначают независимо друг от друга водород или (низш.)алкил, или Rи Rвместе означают -(СН)-, -(СН)- или -(СН)-, или Rили Rмогут быть электронной парой, Rи Rозначают независимо друг от друга водород, алкил, замещенный алкил, циано, галоид, нитро, -SR, -C(O)R, -SOOR, -OSOR, -SONR, -NRSOR, -OC(O)R, -C(O)OR, -C(O)NR, -NRC(O)R, -ORили -NR, Rи R, каждый независимо друг от друга, означают водород, алкил, замещенный алкил, арил, замещенный арил, арил(низш.)алкил, замещенный арил(низш.)алкил, гетероарил(низш.)алкил, замещенный гетероарил(низш.)алкил, гетероциклил, замещенный гетероциклил, гетероарил или замещенный гетероарил, каждый Y независимо друг от друга означает немешающий заместитель, который не связан с нафталиновым кольцом посредством азо- или амидной связи, каждый х независимо друг от друга означает 0, 1 или 2, и линкер соединяет углерод, обозначенный «с», с углеродом, обозначенным «d», или их фармацевтически приемлемые соли, в виде одного стереоизомера или смеси стереоизомеров, применимые для лечения состояний, ассоциированных с гипергликемией, особенно для лечения динафтилмочевинами диабета типа II. Данные соединения применимы для стимуляции киназной активности инсулинового рецептора, активации инсулинового рецептора и стимуляции поглощения глюкозы. Раскрываются также фармацевтические композиции, включающие соединения с антидиабетической активностью.Отчет о международном поиске был опубликован 2001.08.09.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13612899P | 1999-05-26 | 1999-05-26 | |
| PCT/US2000/014644 WO2000071506A2 (en) | 1999-05-26 | 2000-05-25 | Naphthalene ureas as glucose uptake enhancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200101231A1 true EA200101231A1 (ru) | 2002-06-27 |
| EA006763B1 EA006763B1 (ru) | 2006-04-28 |
Family
ID=22471427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200101231A EA006763B1 (ru) | 1999-05-26 | 2000-05-25 | Нафталинмочевины как усилители поглощения глюкозы |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6458998B1 (ru) |
| EP (1) | EP1181271B1 (ru) |
| JP (1) | JP2003500381A (ru) |
| KR (1) | KR100746870B1 (ru) |
| CN (1) | CN1364156A (ru) |
| AR (1) | AR024109A1 (ru) |
| AT (1) | ATE287394T1 (ru) |
| AU (1) | AU776438C (ru) |
| BR (1) | BR0011550A (ru) |
| CA (1) | CA2374225A1 (ru) |
| CZ (1) | CZ20014153A3 (ru) |
| DE (1) | DE60017554T2 (ru) |
| EA (1) | EA006763B1 (ru) |
| ES (1) | ES2233386T3 (ru) |
| HK (1) | HK1046399A1 (ru) |
| HU (1) | HUP0201306A3 (ru) |
| IL (2) | IL146576A0 (ru) |
| MX (1) | MXPA01012079A (ru) |
| NO (1) | NO20015713L (ru) |
| NZ (1) | NZ515743A (ru) |
| PL (1) | PL352631A1 (ru) |
| TR (1) | TR200103409T2 (ru) |
| TW (1) | TWI234557B (ru) |
| UA (1) | UA73738C2 (ru) |
| WO (1) | WO2000071506A2 (ru) |
| ZA (1) | ZA200109641B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7058589B1 (en) * | 1998-12-17 | 2006-06-06 | Iex Corporation | Method and system for employee work scheduling |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| ITTO20010950A1 (it) * | 2000-10-11 | 2003-04-09 | Telik Inc | Attivatori di recettori di insulina per il trattamento di disturbi metabolici in esseri umani che risultano dal trattamento di infezioni da |
| US6528037B2 (en) | 2000-10-11 | 2003-03-04 | Telik, Inc. | Method for determining whether a compound is an insulin receptor kinase activator |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| KR100989394B1 (ko) | 2002-10-21 | 2010-10-25 | 얀센 파마슈티카 엔.브이. | 치환된 테트라린 및 인단 및 그 용도 |
| PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
| NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| IL160420A0 (en) * | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
| ZA200709235B (en) | 2005-04-28 | 2009-09-30 | Ajinomoto Kk | Novel lactam compound |
| EP1893612B1 (en) * | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
| AU2012200933B2 (en) * | 2005-06-22 | 2015-04-30 | Plexxikon, Inc. | Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors |
| RU2008113836A (ru) | 2005-09-09 | 2009-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| PL2414356T3 (pl) | 2009-04-03 | 2016-02-29 | Hoffmann La Roche | Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania |
| NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH488212A (de) * | 1967-09-01 | 1970-03-31 | Ciba Geigy | Photographisches Material |
| US4118232A (en) * | 1971-04-07 | 1978-10-03 | Ciba-Geigy Ag | Photographic material containing sulphonic acid group containing disazo dyestuffs |
| CA987310A (en) * | 1971-04-07 | 1976-04-13 | Ciba-Geigy Ag | Azo dyestuffs, their manufacture and use |
| US4051176A (en) * | 1976-05-10 | 1977-09-27 | American Cyanamid Company | Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds |
| US4129591A (en) * | 1976-10-27 | 1978-12-12 | American Cyanamid Company | Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts |
| US4102917A (en) * | 1977-06-01 | 1978-07-25 | American Cyanamid Company | Substituted phenyl naphthalenesulfonic acids |
| US4132730A (en) * | 1977-07-29 | 1979-01-02 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| US4120891A (en) * | 1977-07-01 | 1978-10-17 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| JPS58191772A (ja) * | 1982-05-06 | 1983-11-09 | Canon Inc | 記録液及びこれを用いたインクジェット記録方法 |
| US4591604A (en) * | 1984-03-28 | 1986-05-27 | American Cyanamid Company | Method of inhibiting the complement system by administering multisulfonated naphthalene ureas |
| DE19521589A1 (de) * | 1995-06-14 | 1996-12-19 | Bayer Ag | Polyfunktionelle Azoreaktivfarbstoffe |
| US5830918A (en) * | 1997-01-15 | 1998-11-03 | Terrapin Technologies, Inc. | Nonpeptide insulin receptor agonists |
| ATE296446T1 (de) * | 1997-01-15 | 2005-06-15 | Telik Inc | Modulatoren von insulinrezeptor-aktivität |
| AU7273598A (en) * | 1997-05-05 | 1998-11-27 | Regents Of The University Of California, The | Naphthols useful in antiviral methods |
-
2000
- 2000-05-20 TW TW089109745A patent/TWI234557B/zh not_active IP Right Cessation
- 2000-05-25 EP EP00936360A patent/EP1181271B1/en not_active Expired - Lifetime
- 2000-05-25 HU HU0201306A patent/HUP0201306A3/hu unknown
- 2000-05-25 EA EA200101231A patent/EA006763B1/ru not_active IP Right Cessation
- 2000-05-25 TR TR2001/03409T patent/TR200103409T2/xx unknown
- 2000-05-25 PL PL00352631A patent/PL352631A1/xx not_active IP Right Cessation
- 2000-05-25 UA UA2001129042A patent/UA73738C2/uk unknown
- 2000-05-25 US US09/579,279 patent/US6458998B1/en not_active Expired - Fee Related
- 2000-05-25 ES ES00936360T patent/ES2233386T3/es not_active Expired - Lifetime
- 2000-05-25 DE DE60017554T patent/DE60017554T2/de not_active Expired - Fee Related
- 2000-05-25 NZ NZ515743A patent/NZ515743A/en unknown
- 2000-05-25 CZ CZ20014153A patent/CZ20014153A3/cs unknown
- 2000-05-25 KR KR1020017015133A patent/KR100746870B1/ko not_active IP Right Cessation
- 2000-05-25 CA CA002374225A patent/CA2374225A1/en not_active Abandoned
- 2000-05-25 AT AT00936360T patent/ATE287394T1/de not_active IP Right Cessation
- 2000-05-25 BR BR0011550-9A patent/BR0011550A/pt not_active Application Discontinuation
- 2000-05-25 WO PCT/US2000/014644 patent/WO2000071506A2/en active IP Right Grant
- 2000-05-25 MX MXPA01012079A patent/MXPA01012079A/es active IP Right Grant
- 2000-05-25 JP JP2000619763A patent/JP2003500381A/ja not_active Withdrawn
- 2000-05-25 IL IL14657600A patent/IL146576A0/xx active IP Right Grant
- 2000-05-25 CN CN00810853A patent/CN1364156A/zh active Pending
- 2000-05-25 AU AU51684/00A patent/AU776438C/en not_active Ceased
- 2000-05-26 AR ARP000102572A patent/AR024109A1/es unknown
-
2001
- 2001-11-19 IL IL146576A patent/IL146576A/en not_active IP Right Cessation
- 2001-11-22 ZA ZA200109641A patent/ZA200109641B/en unknown
- 2001-11-23 NO NO20015713A patent/NO20015713L/no not_active Application Discontinuation
-
2002
- 2002-08-26 HK HK02106271A patent/HK1046399A1/xx not_active IP Right Cessation
- 2002-09-06 US US10/237,583 patent/US7071231B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200101231A1 (ru) | Нафталинмочевины как усилители поглощения глюкозы | |
| ES2291374T3 (es) | Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c. | |
| BG60534B2 (bg) | Уреидо производни на поли-4-амино-2-карбокси-1-метилни съединения | |
| AU3286189A (en) | New, water soluble, antineoplastic derivatives of taxol | |
| ES2117795T3 (es) | Derivados de acetamida y su uso como modificadores del comportamiento de toma alimentaria. | |
| PE20030894A1 (es) | Acridona como inhibidores de la enzima impdh | |
| PE20010152A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| AR004320A1 (es) | Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa. | |
| PL183112B1 (pl) | Nowe pochodne 5-[(2H-pirol-2-ilideno)metylo]-2,2'-bi-1H-pirolu, sposób ich wytwarzania i zawierająca je kompozycja farmaceutyczna | |
| Zhang et al. | Total synthesis of (±) carbocyclic polyoxin C and its α-epimer | |
| Marona et al. | Preliminary evaluation of pharmacological properties of some xanthone derivatives | |
| Kadaba | Triazolines XIII: Δ2-1, 2, 3-Triazolines, a New Class ofAnticonvulsants | |
| Saleh et al. | Synthesis of 3-Guaninyl-and 3-Adeninyl-5-hydroxymethyl-2-pyrrolidinone Nucleosides | |
| Dalençon et al. | Asymmetric synthesis of cyclohexene nucleoside analogues | |
| Dong et al. | Synthesis of novel pleuromutilin derivatives. Part 1: Preliminary studies of antituberculosis activity | |
| de Castro et al. | Novel [2 ‘, 5 ‘-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3 ‘-spiro-5 ‘‘-(4 ‘‘-amino-1 ‘‘, 2 ‘‘-oxathiole-2 ‘‘, 2 ‘‘-dioxide) Derivatives with Anti-HIV-1 and Anti-Human-Cytomegalovirus Activity | |
| EA200200095A1 (ru) | Новые нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозы | |
| Martirosyan et al. | Anti-human immunodeficiency activity of novel 2-arylpyrrolidine analogs | |
| GR3002081T3 (en) | N-2(dimethylamino)ethyl n.(2((2(methylthio)phenyl)(phenylmethyl))amino-2-oxo)ethyl)carbamates or ureas, their preparation and therapeutical use | |
| HUP0302971A2 (hu) | (2-Azabiciklo[2.2.1]hept-7-il)-metanol-származékok, eljárás az előállításukra és nikotinos acetilkolin-receptorok agonistájakénti alkalmazásuk | |
| Guan et al. | Malaria causal prophylactic activity of imidazolidinedione derivatives | |
| Wright et al. | 3‐Bromo N‐Alkyl Cyanamides as Versatile Building Blocks | |
| BR9107299A (pt) | Novo complexo de platina II e processos para sua preparaçao | |
| Guirado et al. | The reaction of 4-amino-2-oxazolines with isocyanates and isothiocyanates. Synthesis and X-ray structures of polysubstituted 2-imidazolidinones, 1, 3-oxazolidines and 1, 3-thiazolidines | |
| Witiak et al. | p-Substituted N-acetyl-L-(S)-and D (R)-. alpha.-amino-N-phenylsuccinimides and-glutarimides. Substituent effects on stereoselective anticonvulsant activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |